Loading…
← CockpitCompetitor Analysis › 300791.SZ Sirio Pharma Co., Ltd. Class AOpen in the cockpit ↗

Sirio Pharma Co., Ltd. Class A300791.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other
Momentum leader 81
Mkt cap
$759M
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$4.50M
20-day average traded
Fwd P/E
16.2×
forward earnings
ROIC−WACC
-2.5 pp
WACC 7.3%
Hurdle
-1 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥16.50
1D-2.4%
1W-2.2%
1M-9.4%
3M-3.7%
6M-6.1%
YTD-36.2%
1Y-30.6%
ATR %3.8%
52w lowhigh37.0% off high

What Sirio Pharma does

Employees: 2,776

Sirio Pharma at a glance

Size Sirio Pharma (300791.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $759M, the 2701st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.50 on 18 Nov 2026.

Performance Over six months the shares fell 6.1%, against -19.1% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 9.2% over the last twelve months (peer median +0.5%); the operating margin is 1.2% (peer median 9.5%).

Valuation It trades at 16.2× forward earnings against a peer median of 20.7× (5th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.5 points below its cost of capital (7.3% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026300791.SZ 94Peer median 81
Six months, rebased to 100: Sirio Pharma against the median of its 20 peers (local-currency closes).

Sirio Pharma financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.04BCN¥4.25BCN¥4.20BCN¥3.57BCN¥2.50B
Revenue growth—+1%+17%+43%—
Gross profitCN¥1.46BCN¥1.22BCN¥1.25BCN¥1.01BCN¥732M
EBITDAn/aCN¥540MCN¥689MCN¥581MCN¥379M
Net incomeCN¥106MCN¥137MCN¥325MCN¥281MCN¥212M
Free cash flowCN¥101MCN¥130MCN¥159M-CN¥63.4MCN¥175M
Capital expenditureCN¥372MCN¥441MCN¥412MCN¥452MCN¥294M
Total debtCN¥2.04BCN¥1.71BCN¥1.62BCN¥1.39BCN¥937M

Quarterly statements and history in the cockpit →

Sirio Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%28776004883000396032620460002562300158PHN0775002219300261APN301507000756AVBP0026440022750024122142CRON300791.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Sirio Pharma is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×200×400×28776032620460PHN002219300261APN3015070007560022752142300791.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sirio Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%600488300039603262002562PHNAPN3015070007560026440022752142CRON300791.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sirio Pharma is the large dot.

Sirio Pharma competitors and peer comparison

How Sirio Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sirio Pharma against its 20 peers (data as of 18 Nov 2026)
Measure300791.SZPeer medianRank in peer set
1-month return-9.4%-9.2%10th lowest of 21
6-month return-6.1%-19.1%5th highest of 21
Distance from 52-week high-37.0%-40.9%9th highest of 21
Revenue growth (TTM)-9.2%+0.5%7th lowest of 20
Operating margin1.2%9.5%5th lowest of 21
Forward P/E16.2×20.7×5th cheapest of 13
Growth the price implies (Req g, 7 yrs)14.1%4.7%6th most demanding of 14
Growth delivered (Del g)+15.6%+12.1%5th highest of 14
Hurdle (Req g minus delivered)-1.4 pp-7.3 pp5th most demanding of 14
ROIC minus cost of capital-2.5 pp+0.4 pp7th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%n/an/an/a
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
ABA Chemicals 300261.SZChina$592M-26%-16%-23%405.0×n/an/a
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%45.4×19.1%+12.1%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%20.0×0.5%+7.9%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%n/an/an/a
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%n/a15.4%+6.5%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%n/a1.4%+7.0%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%

Questions

Which companies are Sirio Pharma's closest peers?
The cockpit's peer set: China Shineway Pharmaceutical (2877.HK), Tianjin Tianyao Pharmaceuticals (600488.SS), Shanghai Kaibao Pharmaceutical (300039.SZ), TSI (603262.SS), Sihuan Pharmaceutical (0460.HK), Brother Enterprises (002562.SZ), Shanxi Zhendong Pharmaceutical (300158.SZ), PharmaNutra (PHN.MI).
Is Sirio Pharma expensive compared with its peers?
On forward p/e it trades at 16.2× against a peer median of 20.7×, 5th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Sirio Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -6.1% against -19.1% for the median peer; over one year -30.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.